REVBW — REVELATION BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1810560 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -3,383,576 | -3,315,513 | 10,022,097 | 9,121,630 | 2,788,395 |
| Jun 2026 | 0 | — | -3,662,241 | -3,323,384 | 12,497,932 | 11,482,792 | 2,430,946 |
| Mar 2026 | 0 | — | -3,092,500 | -3,009,051 | 15,044,282 | 14,113,415 | 2,055,329 |
| Dec 2025 | 0 | — | -2,571,588 | -2,511,006 | 11,582,924 | 10,700,331 | 2,721,929 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,327,937
Investing CF
$-111,507
Financing CF
$15,748,365
CapEx
$-111,507
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-55,751,722
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,269,340
Pretax Income TTM
$-10,750,617
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,070,814 | -8,913,649 | 11,582,924 | 2,721,929 | 8,860,995 | -8,269,581 |
| Dec 2024 | 0 | -7,975,109 | -15,038,536 | 6,622,049 | 1,913,667 | 4,708,382 | -18,321,276 |
| Dec 2023 | 0 | -8,656,664 | -120,254 | 12,212,609 | 5,564,894 | 6,647,715 | -7,286,286 |
| Dec 2022 | 0 | -10,864,511 | -10,829,549 | 5,503,415 | 4,450,962 | 1,052,453 | -11,219,396 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-10,750,617
OpCashFlow TTM
—
Assets (Latest)
$12,497,932
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
2026-11-16 14:00 · Yahoo
REVB Makes Major Announcement
2026-11-16 13:18 · Yahoo
REVB Approaching Important Period in Great Shape
2026-11-06 11:00 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
2026-11-05 22:29 · Yahoo
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
2026-10-16 13:00 · Yahoo
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
2026-08-19 13:00 · Yahoo
REVB Approaching a Critical Inflection Point
2026-08-07 12:14 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
2026-08-06 20:15 · Yahoo
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
2026-08-03 13:00 · Yahoo
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-21 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.